Key Takeaways

• 2A peptide systems outperform IRES in achieving equimolar protein expression, improving therapy reliability.
• Dual 2A systems in human mesenchymal stem cells achieved higher co-expression rates (p < 0.001) than IRES.
• Peptide systems enable co-expression of multiple proteins from a single mRNA, critical for gene circuits and enzymes.
• Industry data shows rising demand for peptide-based therapies, with synthetic biology projects relying on these tools.
• 2A peptides maintain stoichiometric balance in co-expressed proteins, ensuring functional outcomes in multicomponent systems.
• IRES and P2A systems differ mechanistically, impacting efficiency in protein production and gene delivery.
• Efficient co-expression via 2A systems enhances regenerative medicine success through precise gene regulation.

Why Peptide Expression Systems Matter

Peptide expression systems are foundational to advancing biotechnology, healthcare, and synthetic biology by enabling precise control over protein production. These systems address critical challenges in co-expressing multiple genes, a necessity for applications like gene therapy, vaccine development, and metabolic engineering. As the field grows, industry data highlights a surge in peptide-based therapies, with synthetic biology projects increasingly relying on these tools to streamline complex workflows. For example, studies show that 2A peptide systems outperform traditional IRES sequences in achieving equimolar protein expression, directly impacting the reliability of therapies and research outcomes. As mentioned in the Mechanistic Principles of IRES and P2A Systems section, the distinct strategies of these systems underpin their performance differences.

Why Peptide Expression Systems Matter in Modern Biotechnology

Peptide expression systems bridge gaps in protein production by enabling the simultaneous synthesis of multiple proteins from a single mRNA transcript. This is vital for creating functional gene circuits, producing multi-subunit enzymes, or delivering co-factors required for cellular processes. For instance, in human mesenchymal stem cells-a challenging target for genetic modification-researchers found that dual 2A peptide systems achieved significantly higher co-expression rates (p < 0.001) compared to IRES-based approaches. This efficiency is critical for regenerative medicine, where precise gene regulation can determine the success of cell-based therapies. Building on concepts from the Stoichiometric Balance and Co-expressed Proteins section, maintaining balanced protein ratios ensures functional outcomes in multi-protein systems.

The healthcare industry is particularly reliant on these systems. Peptide-based constructs are used to produce therapeutic proteins, such as antibodies and cytokines, and to engineer viral vectors for gene delivery. In agriculture, they help develop crops with enhanced traits by co-expressing multiple genes responsible for stress resistance or nutritional improvements. The ability to control expression stoichiometry ensures that these applications function predictably, reducing trial-and-error costs in development pipelines.

Challenges Addressed by Peptide Expression Systems

Traditional gene expression methods often struggle with inefficiencies like variable translation initiation or unequal protein yields. IRES sequences, while useful, frequently result in downstream gene silencing due to their reliance on cap-dependent translation, which weakens as ribosomes progress along the mRNA. In contrast, 2A peptides exploit ribosome skipping to separate proteins post-translation, achieving cleavage efficiencies of 60–90% depending on the specific peptide variant (e.g., P2A, T2A). This reliability reduces the need for laborious optimization of expression levels, a key bottleneck in protein purification workflows. As detailed in the Cleavage Efficiency and Protein Integrity section, the superior cleavage rates of 2A peptides directly enhance experimental reproducibility.

A study comparing these systems in transgenic mice demonstrated that 2A peptides enabled consistent co-expression of fluorescent reporter proteins, whereas IRES constructs showed erratic downstream expression. For researchers, this means fewer failed experiments and faster validation of hypotheses. Pharmaceutical companies benefit similarly, as these systems streamline the production of complex therapeutics, such as bispecific antibodies or CAR-T cell therapies, where balanced protein ratios are non-negotiable.

Mechanistic Principles of IRES and P2A Systems

When comparing IRES (Internal Ribosome Entry Site) and 2A peptide systems, their mechanistic principles reveal distinct strategies for enabling multicistronic gene expression. Understanding these mechanisms is critical for selecting the right tool for specific experimental or therapeutic applications. Below is a structured analysis of their underlying biology, performance, and use cases..

How IRES Mediates Cap-Independent Translation

IRES elements are RNA sequences derived from viruses (e.g., poliovirus or EMCV) that allow ribosomes to initiate translation internally, bypassing the need for cap-dependent scanning. This mechanism is particularly useful in stress conditions or when the host cell’s translational machinery is compromised. Key features include:

• Structure and Function: IRES elements range from 500–600 base pairs, forming complex secondary structures that recruit ribosomes directly to the start codon of the downstream gene.
• Expression Limitations: Downstream genes in IRES-based systems often exhibit reduced expression levels compared to upstream genes, due to the ribosome’s limited efficiency in reinitiating translation after the first cistron.
• Modification Sensitivity: Studies show that IRES activity is highly sensitive to RNA modifications like N1-methylpseudouridine (m1Ψ). For example, a 25% substitution of uridine with m1Ψ reduces downstream IRES-driven translation by 80% in synthetic mRNA systems.

This mechanism makes IRES suitable for plasmid-based systems or unmodified mRNA applications but less ideal for modified mRNA therapeutics..

How 2A Peptides Enable Ribosomal Skipping

The 2A peptide strategy relies on a viral-derived sequence (e.g., P2A, T2A) that induces “ribosomal skipping” during translation. This process cleaves the nascent polypeptide chain post-translation, allowing two or more proteins to be produced from a single open reading frame. Key attributes include:

• Mechanism: After ribosomes translate the upstream gene, the 2A peptide causes the ribosome to shift, releasing the upstream protein and resuming translation at the downstream gene. This results in equimolar production of all linked proteins.
• Length and Efficiency: 2A peptides are short (~70 base pairs), making them ideal for space-constrained vectors like viral delivery systems. They also exhibit higher translational efficiency in m1Ψ-modified mRNA, where IRES elements falter. For instance, P2A constructs show a 2-fold increase in protein output with full m1Ψ substitution, while IRES constructs are nearly silenced.
• Cleavage Variability: While 2A peptides generally achieve >90% cleavage efficiency in most cell types, incomplete cleavage can lead to fusion proteins or residual dipeptides (e.g., GP or Pro), which may affect product quality in therapeutic contexts. As mentioned in the Cleavage Efficiency and Protein Integrity section, this cleavage variability directly impacts the purity and functionality of the resulting proteins.

This system excels in mRNA-based therapies and applications requiring stoichiometric expression of multiple proteins..

Comparative Analysis: Efficiency, Platform Dependency, and Applications

Feature	IRES Systems	2A Peptide Systems
Translational Efficiency	Lower for downstream genes, especially in modified mRNA	Equimolar expression; higher efficiency in modified mRNA
Platform Performance	Best in plasmid DNA or unmodified mRNA	Superior in m1Ψ-modified mRNA and synthetic mRNA
Vector Size	Larger (~500–600 bp) limits viral vector use	Compact (~70 bp) fits easily into viral vectors. Building on concepts from the Host Cell Considerations and Vector Design section, the compact size of 2A peptides is particularly advantageous for viral vector applications.
Gene Order Impact	Upstream genes dominate expression	All genes expressed at similar levels
Product Quality	Higher purity in antibody production	Risk of aggregation or fusion proteins in CHO cells. As discussed in the Cleavage Efficiency and Protein Integrity section, incomplete 2A cleavage can compromise product quality in therapeutic contexts.

Key Use Cases and Examples

1. IRES Advantages:

• CHO Cell Antibody Production: A study comparing IRES and F2A (a 2A variant) in Chinese hamster ovary (CHO) cells found that IRES-based vectors produced higher-quality monoclonal antibodies with fewer aggregates. However, 2A systems initially showed higher productivity but suffered from cleavage inefficiencies and product instability.
• Unmodified mRNA Therapies: In unmodified mRNA contexts, type I poliovirus IRES outperformed P2A in upstream gene expression, making it suitable for applications where RNA modifications are avoided.

2. 2A Advantages:

• Modified mRNA Vaccines: P2A systems dominate in m1Ψ-modified mRNA due to their resilience to RNA modifications. For example, P2A constructs achieved a 2-fold increase in luciferase activity compared to IRES under full m1Ψ substitution.
• Primary Cell Transfection: In human mesenchymal stem cells (hMSCs), dual 2A peptides (e.g., P2A-T2A) outperformed IRES in co-expressing two reporter genes, achieving co-expression rates 2–3× higher than IRES-based vectors.

Choosing Between IRES and 2A: Key Considerations

• Platform: Use IRES for plasmid DNA or unmodified mRNA; prefer 2A for modified mRNA or circular RNA.
• Modification Needs: Avoid IRES in m1Ψ-modified systems due to its steep sensitivity to nucleotide substitutions.
• Application Requirements: Prioritize IRES for high-purity protein production (e.g., antibodies) and 2A for high-yield, stoichiometric expression in mRNA therapeutics.

In conclusion, the choice between IRES and 2A systems hinges on platform-specific conditions, modification requirements, and downstream product quality needs. While 2A peptides offer broader compatibility with modern mRNA therapies, IRES remains a reliable option in plasmid-based or unmodified RNA contexts.

Cleavage Efficiency and Protein Integrity

P2A peptides generally exhibit higher cleavage efficiency, often approaching 100%, while IRES systems show variable performance depending on the platform and RNA modifications. For a deeper understanding of the underlying mechanisms, refer to the Mechanistic Principles of IRES and P2A Systems section.

In synthetic mRNA, P2A outperforms all IRES types, particularly when the mRNA contains N1-methylpseudouridine (m1Ψ). This sensitivity to RNA modifications ties into broader regulatory challenges discussed in the Regulatory Bottlenecks and Design Trade-offs section.

Protein integrity is a tradeoff between sequence fidelity and expression levels. IRES systems generate unmodified proteins but suffer from poor downstream expression. The impact of stoichiometric balance on functional outcomes is further explored in the Stoichiometric Balance and Co-expressed Proteins section.

In CHO cells, researchers improved F2A performance by adding Gly-Ser-Gly (GSG) spacers and furin cleavage sites, reducing fusion protein formation to 55–62%. Host-specific design considerations are elaborated in the Host Cell Considerations and Vector Design section.

Stoichiometric Balance and Co-expressed Proteins

Stoichiometric balance is critical for functional co-expressed protein complexes. Protein stoichiometry determines the activity of multi-subunit enzymes, receptors, and signaling complexes-imbalances can cause aggregation, toxicity, or loss of function. For instance, a 60% overexpression of one subunit in a heterodimeric enzyme may render the complex inactive. Maintaining equimolar ratios ensures that all components are available in the correct proportions for assembly and function. As mentioned in the Mechanistic Principles of IRES and P2A Systems section, co-expression systems like IRES and P2A differ fundamentally in their translation initiation mechanisms, directly impacting stoichiometric outcomes.

Why Stoichiometric Balance Matters in Co-Expression Systems

IRES (Internal Ribosome Entry Site) and P2A (2A peptide) systems address co-expression but differ in their ability to maintain stoichiometric ratios. IRES relies on cap-independent translation initiation to drive downstream genes, but this often results in unequal expression levels. For example, in a study on monoclonal antibody production, IRES-based vectors showed 30–50% lower downstream gene expression compared to upstream genes. In contrast, P2A peptides use ribosomal skipping to generate equimolar proteins, though fusion proteins can form (e.g., 42% in Sox9-F2A-EGFP constructs). The key distinction lies in platform dependency: P2A excels in modified mRNA systems, while IRES struggles under similar conditions. Building on concepts from the Cleavage Efficiency and Protein Integrity section, P2A’s ribosomal skipping introduces cleavage-dependent risks, such as fusion protein formation, which must be balanced against its equimolar output.

IRES vs. P2A: Performance in Stoichiometric Balance

Factor	IRES	P2A
Expression Efficiency	Lower downstream gene expression (e.g., 20% of upstream in m1Ψ-modified mRNA)	Equimolar expression (e.g., 6× higher EGFP in F2A vs. IRES constructs)
m1Ψ Sensitivity	25% m1Ψ reduces IRES activity by 80%	P2A requires ≥50% m1Ψ for 2× protein output
Fusion Protein Risk	Minimal (no cleavage needed)	High (42–55% fusion proteins in studies)
Platform Suitability	Best in unmodified mRNA or plasmids	Superior in modified mRNA (e.g., vaccines)

In plasmid-based systems, IRES and P2A produce comparable protein levels. However, m1Ψ modification-common in mRNA therapeutics-cripples IRES activity, while P2A thrives. For example, full m1Ψ substitution in mRNA reduces IRES-driven protein output to 20% of P2A’s levels. Conversely, in unmodified mRNA, type-I IRES outperforms P2A by 20–30%. This platform dependency dictates system choice: P2A dominates in modified mRNA, whereas IRES remains viable in plasmid or unmodified RNA contexts.

Factors Affecting Stoichiometric Balance

1. Promoter Strength and Gene Order.
   In IRES systems, upstream genes (e.g., light chain in antibodies) are overexpressed, leading to imbalanced stoichiometry. For instance, in CHO cells, LC-IRES-HC vectors produced 1.5× more light chain than heavy chain, while LC-P2A-HC achieved 1:1 ratios but with 45% aggregation.
2. RNA Modifications.
   N1-methylpseudouridine (m1Ψ) suppresses IRES activity but enhances P2A. At 25% m1Ψ, IRES expression drops 80%, while P2A requires ≥50% m1Ψ to double output. This makes P2A ideal for mRNA vaccines but IRES incompatible with modified mRNAs.
3. Cell-Type Specificity.
   IRES efficiency depends on host factors like PTBP1 (poliovirus IRES). In A549 cells, IRES activity is 50% lower than in HEK293T cells. P2A, however, shows minimal cell-type variability. As discussed in the Host Cell Considerations and Vector Design section, host cell compatibility further complicates IRES performance, necessitating cell-specific optimizations.

Optimization Strategies for Co-Expressed Proteins

1. Use Dual 2A Peptides.
   Combining P2A and T2A (e.g., P2A-T2A) improves cleavage efficiency. In hMSCs, dual 2A systems achieved 80% co-expression compared to 30% with IRES. Building on concepts from the Optimization Strategies and Future Outlook section, strategies like dual 2A linkers are increasingly adopted to mitigate fusion protein risks.
2. Add GSG Spacers.
   Inserting Gly-Ser-Gly (GSG) before P2A enhances cleavage. In Sox9-F2A-EGFP constructs, GSG reduced fusion proteins from 42% to 25%.
3. Avoid EGFP in P2A Systems.
   EGFP inhibits P2A skipping, increasing fusion proteins to 55%. Alternatives like mCherry or tdTomato reduce this effect.
4. Screen IRES Types.
   Among IRES variants (EMCV, HCV, PV), type-I PV IRES is most strong in unmodified mRNA but still underperforms P2A by 40% in modified systems.

Real-World Applications and Outcomes

• Therapeutic Antibodies: IRES-based LC-IRES-HC vectors in CHO cells produced 123 mg/L IgG with <1% aggregation, while P2A systems yielded 75 mg/L with 45% aggregates.
• Vaccines: P2A-linked antigens in m1Ψ-modified mRNA showed 2× higher protein output than IRES, making it the preferred choice for mRNA vaccines.
• Stem Cell Engineering: Dual 2A systems in hMSCs achieved 80% co-expression of EGFP and tdTomato, outperforming IRES by 3×.

In conclusion, stoichiometric balance hinges on linker choice, platform compatibility, and vector design. While IRES offers simplicity in plasmid systems, P2A’s adaptability to modified mRNA and equimolar output make it the gold standard for advanced applications. Researchers must weigh platform-specific constraints and optimize linkers, promoters, and reporters to achieve functional co-expression.

Host Cell Considerations and Vector Design

The choice of host cell and vector design significantly impacts expression efficiency and product quality. Host cells like CHO (Chinese hamster ovary), mammalian cell lines (e.g., A549), and primary stem cells each present unique requirements for linker performance. For instance, in CHO cells, studies show that IRES-based vectors (e.g., EMCV IRES) yield higher-quality monoclonal antibodies with minimal aggregation, whereas P2A (or F2A) systems often result in aggregation and incomplete cleavage, compromising product consistency. As mentioned in the Cleavage Efficiency and Protein Integrity section, aggregation risks in P2A systems stem from suboptimal cleavage, which is less prevalent with IRES in CHO environments.

In contrast, mammalian systems like A549 cells benefit from P2A peptides in synthetic mRNA contexts, especially when modified with N1-methylpseudouridine (m1Ψ), where IRES activity is suppressed. This aligns with findings in the Mechanistic Principles of IRES and P2A Systems section, which highlights how IRES relies on cap-dependent translation while P2A use ribosomal skipping. For primary stem cells, dual 2A peptides (e.g., P2A-T2A) outperform IRES in co-expression efficiency, as demonstrated in human mesenchymal stem cell (hMSC) transfection experiments. This co-expression advantage ties into the Stoichiometric Balance and Co-expressed Proteins section, where maintaining equimolar ratios is critical for functional protein complexes.

Vector design must account for promoter selection, linker sequence, and gene order. In CHO cells, using strong promoters like CMV or EF1α is essential, as downstream gene expression in IRES vectors relies on cap-dependent translation of the first cistron. For P2A systems, adding a Gly-Ser-Gly (GSG) spacer before the linker and a furin cleavage site (RAKR) can improve cleavage efficiency and reduce fusion proteins. Building on concepts from the Mechanistic Principles of IRES and P2A Systems section, gene order in IRES vectors determines expression hierarchy, while P2A systems aim for equal downstream expression levels despite fusion protein risks.

By aligning host-cell capabilities with linker type and vector design, researchers can maximize expression efficiency while minimizing unintended byproducts. Whether targeting biopharma, vaccines, or gene editing, these considerations ensure strong and reproducible outcomes.

Regulatory Bottlenecks and Design Trade-offs

Regulatory bottlenecks in IRES and P2A systems stem from platform-specific dependencies and molecular mechanisms that limit their performance. For instance, IRES elements face significant challenges in modified mRNA contexts. Studies show that N1-methyl-pseudouridine (m1Ψ) modifications suppress IRES activity, with even 25% substitution reducing downstream gene expression by 80% in type-I poliovirus IRES constructs. This sensitivity to RNA modifications creates a bottleneck for mRNA-based therapies where m1Ψ is commonly used to enhance stability. In contrast, P2A peptides thrive in modified mRNA environments, showing a 2-fold increase in protein output with full m1Ψ substitution. However, P2A’s performance is platform-dependent-while it excels in mRNA, its efficiency in plasmid DNA is comparable to IRES but not superior, as detailed in the Stoichiometric Balance and Co-expressed Proteins section.

How Do IRES and P2A Differ in Regulatory Bottlenecks?

The regulatory challenges for IRES and P2A systems diverge based on their molecular mechanisms and platform compatibility (Table 1).

Feature	IRES Bottlenecks	P2A Bottlenecks
mRNA Modification Sensitivity	Strongly suppressed by m1Ψ (25% substitution = 80% drop in expression)	Enhanced by m1Ψ (full substitution = 2x higher expression)
Gene Position Effects	Downstream ORF expression in mRNA is highly sensitive to linker choice	Downstream ORF levels match upstream ORF in both platforms
Platform Compatibility	Works in unmodified mRNA/circular RNA but fails in modified mRNA	Strong in plasmid DNA and modified mRNA
Cell-Type Dependency	Relies on IRES-trans-acting factors (ITAFs) like PTBP1, which vary across cells	Less sensitive to ITAF availability

In unmodified mRNA, IRES elements (e.g., type-I poliovirus IRES) initially outperform P2A for downstream expression, but their activity drops sharply with RNA modifications. This makes IRES unsuitable for most mRNA therapeutics, where m1Ψ is standard. Conversely, P2A’s reliance on ribosomal skipping is less affected by modifications, but its efficiency in plasmid DNA is modest compared to IRES, as discussed in the Mechanistic Principles of IRES and P2A Systems section.

Balancing Expression Levels, Protein Integrity, and Stoichiometry

Design trade-offs between IRES and P2A systems revolve around three key factors: expression levels, protein integrity, and stoichiometric balance.

1. Expression Levels.
   IRES systems often produce downstream proteins at only 10–20% of upstream levels, making them unsuitable for applications requiring equimolar expression. In contrast, P2A peptides enable comparable downstream and upstream expression levels, as seen in mouse models where P2A-based constructs achieved 6-fold higher EGFP signals than IRES-based ones. However, this comes at the cost of partial fusion proteins (e.g., 42% in Sox9-P2A-EGFP constructs), a trade-off addressed in the Cleavage Efficiency and Protein Integrity section.

2. Protein Integrity.
   IRES systems preserve protein sequences, as they do not add residues between ORFs. P2A peptides, while efficient, leave a GP dipeptide on the upstream protein and a proline on the downstream one. These residues can alter protein function, as observed in CHO cells where P2A-based vectors produced aggregates (up to 45% of total protein). Adding a furin cleavage site can mitigate this, but incomplete processing remains a risk.

3. Stoichiometric Balance.
   IRES systems favor upstream ORF expression, which is acceptable for applications where only the second gene needs low levels (e.g., reporters). P2A peptides offer better balance but are not perfect-gene order can still influence efficiency. For example, in plasmid DNA, P2A constructs gave >5× higher upstream expression than IRES in RxG configurations, while in mRNA, downstream expression was comparable to upstream.

Strategies to Optimize Design Trade-Offs

To overcome these bottlenecks, researchers can tailor their approach based on the application:

• For mRNA-based therapies: Prioritize P2A peptides with ≥50% m1Ψ substitution to maximize translation efficiency. Avoid IRES unless using unmodified mRNA or circular RNA platforms.
• For stable cell lines: Use F2A (a P2A variant) in locus-specific knock-ins, but test alternative reporters like FLAG or HA to avoid EGFP-induced cleavage inefficiencies.
• For high-quality protein production: Opt for IRES-based systems, especially in plasmid DNA or unmodified mRNA. LC-first gene order in antibody vectors (e.g., LC-IRES-HC) minimizes aggregation risks.

Real-World Applications of Optimized Designs

• Vaccine Development: P2A-based mRNA vaccines for SARS-CoV-2 use their m1Ψ compatibility to co-express spike and nucleocapsid proteins with 90% cleavage efficiency.
• Antibody Production: IRES-based CHO cell lines producing anti-HER2 IgG1 achieved 123 mg/L titers with <1% aggregation, while P2A variants had 28% aggregates despite higher initial expression.
• Stem Cell Engineering: Dual 2A (P2A-T2A) cassettes in hMSCs outperformed IRES in co-expressing EGFP and tdTomato, achieving 20% co-expression efficiency versus 5% with IRES.

By aligning linker choice with platform requirements and optimizing gene order, researchers can manage these trade-offs effectively. The key is to match the system to the application-P2A for high-expression mRNA therapies, IRES for stable, unmodified contexts.

Optimization Strategies and Future Outlook

Platform-specific factors influencing optimization are deeply tied to the mechanistic differences between IRES and P2A systems, as elaborated in the Mechanistic Principles of IRES and P2A Systems section. For example, P2A peptides thrive in modified mRNA due to their reliance on ribosomal skipping, whereas IRES elements depend on cap-independent translation, a mechanism detailed in the Cleavage Efficiency and Protein Integrity section.

Linker design and codon optimization further intersect with cleavage efficiency and protein fidelity. The Cleavage Efficiency and Protein Integrity section highlights how P2A peptides benefit from spacer sequences like GSG, minimizing residual fusion proteins, while IRES elements require upstream sequences to ensure ribosome recruitment.

For researchers evaluating platform compatibility, the Host Cell Considerations and Vector Design section provides critical insights into how host-specific factors, such as endogenous protease activity, influence P2A-based systems’ fusion protein risks. These considerations underscore the need for tailored linker designs and AI-driven modeling to address platform-specific challenges.

---

Frequently Asked Questions

1. Which system achieves better equimolar protein expression?

2A peptide systems outperform IRES in equimolar expression. Studies show higher co-expression rates (p < 0.001) in human mesenchymal stem cells, ensuring balanced protein ratios critical for functional multicomponent systems.

2. Why are 2A peptides preferred over IRES in some applications?

2A peptides maintain stoichiometric balance by enabling precise co-expression of multiple proteins from a single mRNA. This improves therapy reliability for gene circuits, enzymes, and regenerative medicine applications.

3. Can both IRES and P2A systems co-express multiple proteins?

Yes, but 2A peptides are more efficient. They achieve higher co-expression rates than IRES, especially in complex systems requiring balanced protein ratios like metabolic engineering or synthetic biology projects.

4. How do IRES and P2A systems differ mechanistically?

IRES uses internal ribosome entry for translation, while P2A employs self-cleaving peptides. This difference impacts efficiency, with P2A offering superior equimolar expression and scalability for multigene constructs.

5. What is the impact of 2A systems on therapy reliability?

2A systems enhance reliability by ensuring consistent protein ratios. For example, dual 2A constructs in stem cells improve co-expression success rates, directly affecting outcomes in cell-based therapies and gene circuits.

6. Which system is more widely adopted in synthetic biology?

P2A peptides are increasingly dominant due to rising industry demand. Synthetic biology projects favor them for streamlined workflows, with studies showing their superiority in co-expressing enzymes and gene circuits.

7. How do co-expression rates compare in stem cell studies?

Dual 2A systems achieved significantly higher co-expression rates (p < 0.001) than IRES in human mesenchymal stem cells. This makes 2A more effective for challenging targets in regenerative medicine and gene therapy.